Pharmacokinetic objective

Pharmacodynamic objectives Pharmaceutical objectives Pharmacokinetic objectives... 

Although BA studies have many pharmacokinetic objectives beyond formulation performance as described above, it should be noted that subsequent sections of this guidance focus on using relative BA (referred to as product quality BA) and, in particular, BE studies as a means to document product quality. In vivo performance, in terms of BA/BE, may be considered to be one aspect of product quality that provides a link to the performance of the drug product used in clinical trials and to the database containing evidence of safety and efficacy. 

Pharmacokinetic objectives Improved bioavailability Prolonged duration of action Improved organ selectivity... 

The following points are worthy of note in terms of the placement of data. In the case of studies with multiple objectives, reports should be placed in the section corresponding to their primary purpose. Reports of laboratory studies conducted with human materials to investigate pharmacokinetic effects should be placed in Section 5.3.2 of the clinical module, as opposed to the non-clinical module. A US submission requires that the individual case report forms of all trial subjects that died or were dropped from a study due to adverse events are included in Section 5.3.7. 

The use of antimicrobials for this purpose requires consideration of the types of patients who are at risk the procedures causing bacteremia the organisms that are likely to cause endocarditis and the pharmacokinetics, spectrum, cost, and ease of administration of available agents. The objective... 

Phase I studies evaluate the pharmacokinetics and safety of the drug in a small number (tens) of healthy volunteers. Phase I studies are sometimes conducted in a small patient population (Proof of Concept studies) with a specific objective such as the validation of the relevance of preclinical models in man. The purpose of these studies may be the rapid elimination of potential failures from the pipeline, definition of biological markers for efficacy or toxicity, or demonstration of early evidence of efficacy. These studies have a potential go/no-go decision criteria such as safety, tolerability, bioavailability/PK, pharmacodynamics, and efficacy. Dosage forms used in Phase I or Proof of Concept studies must be developed with the objectives of the clinical study in mind. 

In the last chapter receptor-based diagnostic radiopharmaceuticals are reviewed including considerations on drug design, on receptors, and on receptor imaging with the objective of modifying the pharmacokinetics of these agents. 

In the development of most new active substances, it is required to investigate the disposition of the compound and its metabolite(s) and their rates and routes of elimination. This is generally carried out with radiolabelled compound, usually In the United Kingdom, approval of the Administration of Radioactive Substances Advisory Committee (ARSAC) is required for administration of radiolabelled compound to man. The purpose of the submission is to demonstrate that the dose of absorbed radiation is minimised by administration of the lowest dose that is consistent with meeting the objectives of the study. In general, the estimated absorbed radiation dose should be less than 500 xSv, but higher amoimts are permissible if they can be justified. The estimate is based on tissue distribution of radioactivity in animals and the pharmacokinetics in animals and man. 

First, they can be used to generate hypotheses. Because of their nature when data are extracted from the literature across diverse study protocols meta-analyses can be extremely useful in generating h)rpotheses particularly concerning subgroups of patients. In this sense their use mirrors one potential objective of a population pharmacokinetic study that may be to determine interesting covaiiates, which influence drug... 

The analysis of samples obtained from physiological matrices has been the object of many reports on the use of Rlk]. This use can be expected to expand in response to the need to understand the pharmacodynamics and pharmacokinetics of various pharmaceutical agents. In addition, the versatility of RPC will facilitate the analysis of various metabolites and,... 

---